New state pharma company - ENFARMA - created in Ecuador
By an executive Decree (No 181) in late December 2009, the Ecuadorian President, Rafael Correa, ordered the creation of a public pharmaceutical company called ENFARMA PA, in what looks to local observers like an attempt by the government to monopolize the drug industry.
The purpose of this company includes R&D of active ingredients for the manufacture of drugs for human and veterinary use, and agronomic. Besides, it will produce medicines already patented - relating to the recent announcement of compulsory licenses in the country. The company will also be involved with the marketing, import, export, packaging, labeling and distribution of drugs.
The company will be responsible for the development of scientific research, experimental programs and technological improvement in pharmaceutical matters and the elaboration of general programs for the promotion and diffusion of the generic medicine use and other drugs.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze